Skip to main content
Clinical Trials/ISRCTN16919107
ISRCTN16919107
Completed
Not Applicable

Clinical and laryngoscopic predictors of symptomatic response to pantoprazole magnesium in patients with newly diagnosed laryngopharyngeal reflux: a prospective study

Takeda Pharmaceutical Company Limited0 sites100 target enrollmentAugust 17, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Laryngopharyngeal reflux
Sponsor
Takeda Pharmaceutical Company Limited
Enrollment
100
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 17, 2016
End Date
TBD
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Aged 18 years and over
  • 2\. Chief complaint of hoarseness, sore throat, throat burning/pain, throat clearing, voice loss, cough, excessive throat mucus, globus, or choking for at least 4 weeks in the preceding 3 months

Exclusion Criteria

  • 1\. Patients younger than age 18
  • 2\. Patients with identifiable laryngeal pathology
  • 3\. Upper respiratory tract infection in the past 4 weeks
  • 4\. Identifiable allergic causes of laryngitis
  • 5\. Previous laryngeal malignancy, surgery or radiotherapy
  • 6\. Women of childbearing potential not using an effective contraceptive method
  • 7\. Acid\-suppressive therapy within the past 4 weeks
  • 8\. Hypersensitivity to the active ingredient, or to any of the excipients of the product
  • 9\. Patients taking HIV protease inhibitors or methotrexate

Outcomes

Primary Outcomes

Not specified

Similar Trials